



Uscom Limited
ABN 35 091 028 090
Suite 1, Level 7, 10 Loftus Street
Sydney NSW 2000 Australia
T +612 9247 4144 F +612 9247 8157
www.uscom.com.au

MARKET ANNOUNCEMENT

New US Uscom BP+ Patent

New methods approved for heart failure, hypertension and vascular health

SYDNEY, Australia, Monday 11th July 2016: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical devices company, today notified the market of the receipt of a Notice of Allowance from the United States Patent and Trademarks Office for the patent covering the central algorithms in the Uscom BP+ suprasystolic oscillometric central blood pressure monitor. The Patent has a priority date of 13th May 2009.

The patent covers the key central pressure calculations made by the suprasystolic Uscom BP+ to measure the blood pressure wave forms generated at the heart. This provides for more direct measures than simple blood pressure measures made at the arm, as is common in most current technologies. The Uscom BP+ represents some of the most advanced and innovative cardiovascular technology generating pressure wave-form measures only previously available using cardiac catheters, and improving the diagnosis and management of hypertension and heart failure.

Central blood pressure measurements and wave form analysis are an emerging standard of care for the evaluation of cardiovascular physiology and disease, and the current Uscom patent combined with the prior suprasystolic patents ensures that the Uscom BP+ innovation is commercially protected. Central blood pressure measurement is currently re-imbursed in the USA, and the Uscom BP+ device is being prepared for release into the USA market, and is expected to retail at approximately US\$3,000, significantly lower than most of its competitors which range as high as US\$20,000.

Monitoring the effectiveness of drug treatments in hypertension and heart failure is a major application of the Uscom BP+ and a number of major pharmaceutical companies are currently investigating the Uscom BP+ technology. A leading European drug company is currently using the devices in a trial of hypertensive drugs with results expected mid next year. Ten BP+ units are currently being used by a leading UK research team studying the effects of altitude on hypertension on Mount Everest. The Uscom BP+ is also currently in use on the International Space Station.

Executive Chairman of Uscom, Associate Professor Rob Phillips said *"Our company is built on scientific excellence, and our strategy is to produce the most advanced blood pressure monitor available at a much reduced price to our competitors. We are targeting the US market and the pharmaceutical companies which are in need of novel and reliable technologies to significantly improve measurement, monitoring and treatment of hypertension and heart failure. It's a very exciting time for us as we prepare the Uscom BP+ for China, European and USA release. The Uscom BP+ device will transform the revenue base of our company and will be imported into China by our new CIIC partners."*

Uscom management is focused on becoming a multi-technology, fast growth, international medical device company selling a sophisticated and profitable suite of non-invasive, sector leading technologies into world medical markets. Uscom management continues to focus on active growth strategies and optimising long term shareholder value."

References: 1. Stoner L, Lambrick DM, Westrupp N, Young J, Faulkner J. Validation of Oscillometric Pulse Wave Analysis Measurements in Children. American Journal of Hypertension 2014, doi:10.1093/ajh/hpt243. 2. Lydakis C, Stefanaki E, Stefanaki S, Thalassinou E, Kavousanaki M, Lydaki D. Correlation of Blood Pressure, Obesity, and Adherence to the Mediterranean Diet with Indices of arterial Stiffness in Children. Eur J Pediatr (2012) 171:1373–1382 DOI 10.1007/s00431-012-1735-3. 3. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014; doi:10.1093/eurheartj/ehu565. 4. Avolio A. Central aortic blood pressure and management of hypertension: confirmation of a paradigm shift? Hypertension Editorial 2013; Sept 23



Uscom Limited

ABN 35 091 028 090

Suite 1, Level 7, 10 Loftus Street

Sydney NSW 2000 Australia

T +612 9247 4144 F +612 9247 8157

www.uscom.com.au

MARKET ANNOUNCEMENT

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Devices are clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary
secretary@uscom.com.au